Results 81 to 90 of about 125,001 (364)

Periodontitis and atherosclerotic cardiovascular disease: A critical appraisal

Periodontology 2000, EarlyView., 2023
Abstract In spite of intensive research efforts driving spectacular advances in terms of prevention and treatments, cardiovascular diseases (CVDs) remain a leading health burden, accounting for 32% of all deaths (World Health Organization. “Cardiovascular Diseases (CVDs).” WHO, February 1, 2017, https://www.who.int/news‐room/fact‐sheets/detail ...
Maria Clotilde Carra, Hélène Rangé, Giuseppina Caligiuri, Philippe Bouchard   +3 more
wiley   +1 more source

Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease

BMC Cardiovascular Disorders, 2022
Backgrounds Remarkable interindividual variability in clopidogrel response is observed, genetic polymorphisms in P2RY12 and its signal pathway is supposed to affect clopidogrel response in CHD patients.
Yan-Jiao Zhang, Dong-Jie Li, Zhong-Yi Li, Xiao-Lei Hu, He Li, Qi-Lin Ma, Xiao-Ping Chen   +6 more
doaj   +1 more source

Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke:Pooled analysis of randomized trials [PDF]

, 2015
Background and Purpose: Lacunar stroke accounts for ≈25% of ischemic stroke, but optimal antiplatelet regimen to prevent stroke recurrence remains unclear.
Benavente, Oscar R., Copley, Hannah Charlotte, Kwok, Chun Shing, Loke, Yoon K., Myint, Phyo Kyaw, Shoamanesh, Ashkan   +5 more
core   +1 more source

Artesunate Inhibits Neointimal Hyperplasia by Promoting IRF4 Associated Macrophage Polarization

Advanced Science, EarlyView.
This study shows that macrophage interferon regulatory factor 4 (IRF4) improved arterial injury‐induced neointimal hyperplasia by promoting of M2 polarization via up‐regulating krüppel‐like factor 4 (KLF4) in rodent and nonhuman primate models. Notably, artesunate is identified as a potent inducer of IRF4 in macrophages, and proposed as a promising ...
Jinlin Miao, Yule Yong, Zhaohui Zheng, Kui Zhang, Wei Li, Jiayi Liu, Siyi Zhou, Juan‐juan Qin, Haoyang Sun, Yatao Wang, Xianghui Fu, Xing Luo, Siyu Chen, Zhi‐Gang She, Jingjing Cai, Ping Zhu   +15 more
wiley   +1 more source

Severe hyperferremia and hyperferritinemia in a dog with precursor‐directed immune‐mediated anemia

Veterinary Clinical Pathology, Volume 51, Issue 4, Page 491-494, December 2022., 2022
Abstract A 4‐year‐old dog was evaluated at the Colorado State University Veterinary Teaching Hospital for lethargy and hyporexia of 24 hours duration. On presentation, she had a marked normocytic, normochromic, nonregenerative anemia (HCT 14%; RI 40–55).
Kristin M. Zersen, Carly W. Gregory, Christina M. Jeffries, Christine Olver   +3 more
wiley   +1 more source

Upper gastrointestinal lesions in patients receiving clopidogrel anti-platelet therapy

Journal of the Formosan Medical Association, 2012
Clopidogrel is associated with a high incidence of upper gastrointestinal bleeding in high-risk patients. However, the characteristic upper gastrointestinal lesions in symptomatic clopidogrel users remain unclear.
Tzung-Jiun Tsai, Kwok-Hung Lai, Ping-I. Hsu, Chiun-Ku Lin, Hoi-Hung Chan, Hsien-Chung Yu, Huay-Min Wang, Kung-Hung Lin, Kai-Ming Wang, Shiuh-Nan Chang, Chun-Peng Liu, Shin-Hung Hsiao, Hung-Ru Huang, Ching-Huang Lin, Feng-Woei Tsay   +14 more
doaj   +1 more source

P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes

Journal of Interventional Cardiology, 2023
Background. Randomized trials have shown superiority of the novel P2Y12 inhibitors over clopidogrel in patients with acute coronary syndrome (ACS), but clinical benefit in the community remains controversial.
Amit Sachdeva, Ratnabhushan Mutyala, Neha Mantri, Shiyun Zhu, Edward McNulty, Matthew Solomon   +5 more
doaj   +1 more source

Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: A Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials.

JAMA Neurology, 2019
Importance Dual antiplatelet therapy with clopidogrel and aspirin is effective for secondary prevention after minor ischemic stroke or transient ischemic attack (TIA).
Yuesong Pan, J. Elm, Hao Li, J. Easton, Yilong Wang, M. Farrant, Xia Meng, A. Kim, Xingquan Zhao, W. Meurer, Liping Liu, D. Dietrich, Yongjun Wang, S. Johnston   +13 more
semanticscholar   +1 more source

Clopidogrel: A multifaceted affair [PDF]

The Journal of Clinical Pharmacology, 2014
AbstractClopidogrel has been the therapy of choice, combined with aspirin, against platelet aggregation in patients at risk of suffering a vascular thrombotic event. Not all patients respond equally to clopidogrel, an observation that has led to searching for a test that, in the clinical setting, could predict patients' “resistance” to therapy.
Antonio Tugores, Efrén Martínez-Quintana   +1 more
openaire   +4 more sources

Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease. [PDF]

PLoS ONE, 2014
Clopidogrel is an antiplatelet prodrug that is recommended to reduce the risk of recurrent thrombosis in coronary artery disease (CAD) patients. Paraoxonase 1 (PON1) is suggested to be a rate-limiting enzyme in the conversion of 2-oxo-clopidogrel to ...
Damrus Tresukosol, Bhoom Suktitipat, Saowalak Hunnangkul, Ruttakarn Kamkaew, Saiphon Poldee, Boonrat Tassaneetrithep, Atip Likidlilid   +6 more
doaj   +1 more source